GlassScriptPhysician profile
Mary I Cady
NPI 1427097385
$889.25
in general payments reported to CMS, 2019-2025
21 companies · $308 in 2025
The $308 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.02 · 2021: $146 · 2022: $291 · 2023: $38.11 · 2024: $33.76 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $379.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $99.82 | 2025 | Zurzuvae |
| Abbvie INC. | $95.00 | 2021-2025 | |
| Astellas Pharma US INC | $76.47 | 2021-2022 | |
| Amgen INC. | $74.24 | 2019-2022 | |
| Boston Scientific Corporation | $72.62 | 2019-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $70.08 | 2021-2022 | |
| Lilly USA, LLC | $66.47 | 2022-2025 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.64 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.87 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $30.63 | 2022-2025 | Breztri |
| Eisai INC. | $28.57 | 2025 | |
| Amarin Pharma, INC. | $22.07 | 2019 | |
| Abbott Laboratories | $21.53 | 2023 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.26 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $17.89 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $16.98 | 2024 | Slynd |
| Sage Therapeutics, LLC | $16.78 | 2024 | |
| Merck Sharp & Dohme LLC | $15.54 | 2022 | |
| Optinose US, INC. | $15.20 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.26 | 2022 | |
| Novo Nordisk INC | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Cady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.